Despite a series of methodological limitations and the fact that not all samples were evaluable for these markers, we did not find actionable fusions, TMB high, or MSI in any case, which suggests the limited applicability of the concept of tumor-agnostic therapies in standard clinical practice for ER+/HER2- MBC (8). Here, ERBB2 is linked to neoplasm.